WO2021145672A1 - Arginine aspartate-containing composition for suppressing old person smell - Google Patents
Arginine aspartate-containing composition for suppressing old person smell Download PDFInfo
- Publication number
- WO2021145672A1 WO2021145672A1 PCT/KR2021/000470 KR2021000470W WO2021145672A1 WO 2021145672 A1 WO2021145672 A1 WO 2021145672A1 KR 2021000470 W KR2021000470 W KR 2021000470W WO 2021145672 A1 WO2021145672 A1 WO 2021145672A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arginine aspartate
- nonenal
- body odor
- present
- arginine
- Prior art date
Links
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 title claims abstract description 46
- 229960002223 arginine aspartate Drugs 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- BSAIUMLZVGUGKX-UHFFFAOYSA-N 2-Nonenal Natural products CCCCCCC=CC=O BSAIUMLZVGUGKX-UHFFFAOYSA-N 0.000 claims abstract description 33
- 230000002087 whitening effect Effects 0.000 claims abstract description 13
- 230000037303 wrinkles Effects 0.000 claims abstract description 12
- BSAIUMLZVGUGKX-BQYQJAHWSA-N (E)-non-2-enal Chemical compound CCCCCC\C=C\C=O BSAIUMLZVGUGKX-BQYQJAHWSA-N 0.000 claims abstract 4
- 208000035985 Body Odor Diseases 0.000 claims description 26
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 230000002431 foraging effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 14
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract description 12
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract description 12
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 102000003425 Tyrosinase Human genes 0.000 abstract description 5
- 108060008724 Tyrosinase Proteins 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- BSAIUMLZVGUGKX-FPLPWBNLSA-N 2-nonenal Chemical compound CCCCCC\C=C/C=O BSAIUMLZVGUGKX-FPLPWBNLSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 239000013641 positive control Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- -1 tracanth Substances 0.000 description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 101100114416 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-10 gene Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000010639 cypress oil Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to a composition for inhibiting senile body odor containing arginine aspartate, and more particularly, to a composition capable of inhibiting senile body odor by removing 2-nonenal containing arginine aspartate.
- Wastes in the body accumulate in the body due to the deterioration of the metabolic ability due to aging of the body and the function of decomposition and excretion is not smooth.
- a substance called 2-nonenal is one of the causes of body odor in middle-aged men, especially in large amounts on the back and chest.
- omega-7 fatty acids such as 9-hexadecenoic acid increase in lipids, and these fatty acids are oxidized and decomposed to produce 2-nonenal. Omega-7 fatty acids are decomposed into 4-hydroxy-2-nonenal before the age of 40, but with aging, it is converted to 2-nonenal due to an increase in omega-7 fatty acids, a decrease in metabolism, and a decrease in antioxidant function. Decomposition increases and accumulates, causing senile body odor.
- Korean Patent Registration No. 10-1627415 discloses a cosmetic composition capable of removing nonenal, which causes senile malodor, a cosmetic composition containing a lysosomal extract, a cypress extract and a herbal extract.
- Korean Patent Laid-Open No. 10-2013-0150408 discloses an antinonenal deodorant composition containing essential cypress oil and seaweed extract.
- arginine aspartate effectively removes 2-nonenal to suppress senile body odor.
- arginine aspartate has wrinkle improvement, anti-inflammatory or whitening effects in addition to the senile body odor suppression effect, and completed the present invention.
- One embodiment of the present invention relates to a cosmetic composition for suppressing senile body odor, improving wrinkles, and anti-inflammatory or whitening, comprising arginine aspartate.
- the arginine aspartate is a salt formed of L-arginine, which is a basic amino acid, and L-aspartic acid, which is an acidic amino acid.
- the arginine aspartate may be represented by the following formula (1).
- the arginine aspartate can be obtained commercially or can be easily prepared by methods known in the art.
- Arginine aspartate according to the present invention not only reduces 2-nonenal, but also inhibits MMP-1 (matrix metalloproteinase-1) expression, has collagen synthesis ability, reduces TNF- ⁇ expression, and tyro It was shown to inhibit the activity of the kinase (Experimental Examples 1 to 5). Therefore, the arginine aspartate according to the present invention can be effectively used in a composition for inhibiting senile body odor, improving wrinkles, anti-inflammatory or whitening, and in particular, it can be used in a composition for inhibiting senile body odor that reduces 2-nonenal.
- MMP-1 matrix metalloproteinase-1
- the cosmetic composition according to the present invention contains the arginine aspartate as an active ingredient in an amount of about 0.001 to 10% by weight, preferably 0.01 to 5% by weight.
- the content of the active ingredient may be appropriately determined according to the purpose of its use.
- the cosmetic composition of the present invention includes components commonly used in cosmetic compositions in addition to the arginine aspartate, for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers. .
- the cosmetic composition of the present invention may be prepared in any formulation commonly used in the art, for example, it may be formulated as a solution, suspension, emulsion, paste, gel, cream, powder, spray, and the like.
- the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. may be used as a carrier component.
- lactose When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component.
- additional chlorofluorohydrocarbon In particular, in the case of a spray, additional chlorofluorohydrocarbon, It may contain propellants such as propane/butane or dimethyl ether.
- a solvent for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylglycol oil, glycerol fatty acid ester, polyethylene glycol, fatty acid ester of sorbitan, etc.
- solubilizer or emulsifier for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylglycol oil, glycerol fatty acid ester, polyethylene glycol, fatty acid ester of sorbitan, etc.
- the formulation of the present invention is a suspension
- a liquid diluent such as water, ethanol or propylene glycol
- a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester or polyoxyethylene sorbitan ester, microcrystals
- the cosmetic composition of the present invention includes skin, lotion, cream, essence, pack, foundation, color cosmetics, sun cream, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, and eyebrow pencil. It can be applied to cosmetics such as
- One embodiment of the present invention relates to a pharmaceutical composition for suppressing senile body odor, wrinkle improvement, anti-inflammatory or whitening comprising arginine aspartate.
- the pharmaceutical composition may be a pharmaceutical composition for inhibiting senile body odor that reduces 2-nonenal.
- the pharmaceutical composition according to the present invention may be administered orally (eg, taking or inhalation) or parenterally (eg, injection, transdermal absorption, rectal administration), and injection is, for example, intravenous injection , subcutaneous injection, intramuscular injection or intraperitoneal injection.
- the pharmaceutical composition according to the present invention may be administered as a tablet, capsule, granule, fine subtilae, powder, sublingual tablet, suppository, ointment, injection, emulsion, suspension, syrup, spray, etc., depending on the route of administration. can be formulated.
- the various types of the pharmaceutical composition according to the present invention can be prepared by known techniques using a pharmaceutically acceptable carrier commonly used for each formulation.
- Examples of pharmaceutically acceptable carriers include excipients, binders, disintegrating agents, lubricants, preservatives, antioxidants, isotonic agents, buffers, coating agents, sweetening agents, solubilizing agents, bases, dispersing agents, wetting agents , suspending agents, stabilizing agents, coloring agents, and the like.
- the pharmaceutical composition according to the present invention varies depending on the form of the drug, but contains the arginine aspartate in an amount of about 0.001 to 10% by weight, preferably 0.01 to 2% by weight.
- the specific dosage of the pharmaceutical composition of the present invention may vary depending on the type of mammal, including the person to be treated, body weight, sex, degree of disease, judgment of a doctor, and the like.
- 10 to 200 mg of the active ingredient per 1 kg of body weight is administered per day.
- the total daily dose may be administered at one time or divided into several doses depending on the severity of the disease, the judgment of the doctor, and the like.
- One embodiment of the present invention relates to a functional food for inhibiting senile body odor, wrinkle improvement, anti-inflammatory or whitening containing arginine aspartate.
- the health functional food may be a health functional food for suppressing senile body odor that reduces 2-nonenal.
- the type of health functional food according to the present invention is not particularly limited, and is in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, or candies, confectionery, gum, ice cream, noodles, bread, It can be added to general foods such as beverages.
- the health functional food of the present invention can be prepared by appropriately using a food-logically acceptable carrier such as a filler, an extender, a binder, a wetting agent, a disintegrant, a sweetener, a fragrance, a preservative, a surfactant, a lubricant, and an excipient in a conventional manner depending on the form.
- a food-logically acceptable carrier such as a filler, an extender, a binder, a wetting agent, a disintegrant, a sweetener, a fragrance, a preservative, a surfactant, a lubricant, and an excipient in a conventional manner depending on the form.
- the content of the arginine aspartate varies depending on the type of health functional food, but is about 0.001 to 10 wt%, preferably 0.1 to 5 wt%.
- Arginine aspartate according to the present invention not only reduces 2-nonenal, but also inhibits MMP-1 (matrix metalloproteinase-1) expression, has collagen synthesis ability, reduces TNF- ⁇ expression, and tyro Since it can inhibit the activity of synase, it can be effectively used in a composition for inhibiting senile body odor, improving wrinkles, and anti-inflammatory or whitening.
- MMP-1 matrix metalloproteinase-1
- 1 is a graph showing the evaluation results of 2-nonenal removal ability of arginine aspartate.
- 2-Nonenal was dissolved at a concentration of 0.1 wt% (1000 ppm) in 50 wt% ethanol aqueous solution containing 0.5 wt% tween 80.
- Arginine aspartate was dissolved in a 50 wt% ethanol aqueous solution containing 0.5 wt% Tween 80 at a concentration of 5 wt% (50000 ppm).
- the two solutions were mixed at a ratio of 1:1 by weight, and the change in the amount of 2-nonenal was analyzed by HPLC over time while standing at room temperature. That is, the change in the amount of 2-nonenal with time was analyzed by treating arginine aspartate at a concentration of 2.5 wt% in 0.05 wt% of 2-nonenal.
- the 2-nonenal solution prepared above was diluted two-fold with a 50 wt% ethanol aqueous solution containing 0.5 wt% Tween 80, and the change in the amount of 2-nonenal was analyzed by HPLC over time while standing at room temperature. That is, the change in the amount of 2-nonenal with time was analyzed by creating a condition of 0.05 wt% of arginine aspartate untreated 2-nonenal.
- Human skin fibroblasts were cultured at a concentration of 1 ⁇ 10 4 /well.
- the cells were treated with arginine aspartate by concentration, and the MMP-1 expression level was measured using a PCR device to evaluate the MMP-1 inhibitory ability.
- a case in which the sample was not treated was used as a control group (CON), and 50 ppm of adenosine was treated as a positive control group. The results are shown in Table 1 below.
- MMP-1 gene expression level (MMP-1 gene expression level) (% of control) Concentration (ppm) CON 10 20 40 Arginine Aspartate 100 86.7 82.2 76.6 Adenosine (50 ppm) 73.9
- Example 3 Collagen synthesis ability evaluation
- Human skin fibroblasts were cultured at a concentration of 1 ⁇ 10 4 /well. Each sample was treated in the cells and the collagen synthesis ability was evaluated by measuring the amount of collagen synthesis. As a positive control, adenosine was treated at a concentration of 50 ppm, and arginine aspartate was treated at a concentration of 10, 20 and 40 ppm. Collagen quantification was performed using a Type I Procollagen C-Peptide EIA kit (Takara, Japan). The case where the sample was not treated was used as a control (CON). The results are shown in Table 2 below.
- arginine aspartate according to the present invention showed an increase in collagen synthesis compared to the control group (CON).
- arginine aspartate according to the present invention exhibited an increase in collagen synthesis at a concentration of 40 ppm, similar to the case of treatment with adenosine, a positive control, at a concentration of 50 ppm.
- HaCaT cells were seeded in a 12-well plate by 1 ⁇ 10 5 cells/well, and replaced with a basal medium after 24 hours, followed by starvation treatment for 6 hours. After that, it was replaced with the basal medium containing the sample and cultured for 24 hours. After removing the medium, UVB stimulation was applied, and the basal medium was added and cultured for 24 hours. The medium was completely removed and washed twice with PBS. Cells were disrupted using TRIsure to recover RNA, and then RT-PCR was performed to amplify TNF- ⁇ . Electrophoresis was performed on an agarose gel and the expression rate was measured using the Gel Documentation system. 200 ⁇ M dexamethasone was used as a positive control. The results are shown in Table 3 below.
- TNF- ⁇ expression level decreased by 37.4% at a concentration of 40 ppm of arginine aspartate. This was shown to be similar to the ability to inhibit the expression of TNF- ⁇ at a concentration of 200 ⁇ M of dexamethasone as a positive control.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
구분division |
MMP-1 유전자 발현 수준(MMP-1 gene expression level) (% of control)MMP-1 gene expression level (MMP-1 gene expression level) (% of control) |
|||
농도(ppm)Concentration (ppm) |
CON |
1010 | 2020 | 4040 |
알지닌 아스파테이트 |
100100 | 86.786.7 | 82.282.2 | 76.676.6 |
아데노신(50 ppm)Adenosine (50 ppm) | 73.973.9 |
구분division |
프로콜라겐 유전자 발현 수준 (% of control)Procollagen gene expression level (% of control) |
|||
농도(ppm)Concentration (ppm) |
CON |
1010 | 2020 | 4040 |
알지닌 아스파테이트Arginine Aspartate | 100.0100.0 | 123.6123.6 | 133.0133.0 | 136.8136.8 |
아데노신(50 ppm)Adenosine (50 ppm) | 142.2142.2 |
구분division |
TNF-α 유전자 발현 수준 (% of control)TNF-α gene expression level (% of control) |
|||
농도(ppm)Concentration (ppm) |
CON |
1010 | 2020 | 4040 |
알지닌 아스파테이트Arginine Aspartate | 100.0100.0 | 76.076.0 | 72.972.9 | 72.672.6 |
덱사메타손 (200 μM)Dexamethasone (200 μM) | 66.966.9 |
구분division | 티로시나제 활성 (% of control)Tyrosinase activity (% of control) | ||
농도(ppm)Concentration (ppm) |
CON |
1010 | 100100 |
알지닌 아스파테이트 |
100100 | 72.572.5 | 71.771.7 |
알부틴(100ppm)Arbutin (100ppm) | 93.693.6 | 76.776.7 |
Claims (9)
- 알지닌 아스파테이트를 포함하는 노인성 체취 억제, 주름개선, 항염 또는 미백용 화장료 조성물.A cosmetic composition for suppressing senile body odor, improving wrinkles, and for anti-inflammatory or whitening, comprising arginine aspartate.
- 제1항에 있어서, 2-노네날을 감소시키는 노인성 체취 억제용 화장료 조성물.[Claim 2] The cosmetic composition for inhibiting body odor in the elderly according to claim 1, which reduces 2-nonenal.
- 알지닌 아스파테이트를 포함하는 노인성 체취 억제, 주름개선, 항염 또는 미백용 약제학적 조성물.A pharmaceutical composition for suppressing senile body odor, improving wrinkles, anti-inflammatory or whitening, comprising arginine aspartate.
- 제4항에 있어서, 2-노네날을 감소시키는 노인성 체취 억제용 약제학적 조성물.[Claim 5] The pharmaceutical composition for inhibiting body odor in the elderly according to claim 4, which reduces 2-nonenal.
- 알지닌 아스파테이트를 포함하는 노인성 체취 억제, 주름개선, 항염 또는 미백용 건강기능식품.Health functional food for aging body odor suppression, wrinkle improvement, anti-inflammatory or whitening containing arginine aspartate.
- 제7항에 있어서, 상기 알지닌 아스파테이트는 하기 화학식 1로 표시되는 것인 노인성 체취 억제, 주름개선, 항염 또는 미백용 건강기능식품:According to claim 7, wherein the arginine aspartate is a health functional food for senile body odor suppression, wrinkle improvement, anti-inflammatory or whitening that is represented by the following Chemical Formula 1:[화학식 1] [Formula 1]
- 제7항에 있어서, 2-노네날을 감소시키는 노인성 체취 억제용 건강기능식품.[Claim 8] The health functional food for suppressing senile body odor according to claim 7, which reduces 2-nonenal.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022568367A JP2023510655A (en) | 2020-01-15 | 2021-01-13 | Composition for suppressing aging odor containing arginine aspartate |
CN202180009069.9A CN114980856A (en) | 2020-01-15 | 2021-01-13 | Composition comprising arginine aspartate for suppressing the odor of elderly people |
US17/792,844 US20230056593A1 (en) | 2020-01-15 | 2021-01-13 | Arginine aspartate-containing composition for suppressing old person smell |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200005364A KR102315140B1 (en) | 2020-01-15 | 2020-01-15 | Composition for Inhibiting Aging Odor Comprising Arginine Aspartate |
KR10-2020-0005364 | 2020-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021145672A1 true WO2021145672A1 (en) | 2021-07-22 |
Family
ID=76864540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/000470 WO2021145672A1 (en) | 2020-01-15 | 2021-01-13 | Arginine aspartate-containing composition for suppressing old person smell |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230056593A1 (en) |
JP (1) | JP2023510655A (en) |
KR (1) | KR102315140B1 (en) |
CN (1) | CN114980856A (en) |
WO (1) | WO2021145672A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5019558A (en) * | 1988-05-09 | 1991-05-28 | Georges Cehovic | Method for treating memory disturbances using arginine aspartate |
WO1996028008A2 (en) * | 1996-03-19 | 1996-09-19 | Guerlain S.A. | Novel cosmetic or dermatological compositions for controlling skin ageing |
KR20120118222A (en) * | 2011-04-18 | 2012-10-26 | 상황미인(주) | Cosmetic composition for deoderizing odl men smell by using orental natural materials |
KR20130083103A (en) * | 2012-01-12 | 2013-07-22 | (주)와이즈덤레버러토리 | Anti-aging peptides having depigmentation, anti-wrinkle, anti-oxidation, hair-growth, and angiogenic activities, and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2373864T3 (en) * | 1998-04-20 | 2012-02-09 | Eisai R&D Management Co., Ltd. | STABILIZED COMPOSITION CONTAINING A BENCIMIDAZOL TYPE COMPOSITE. |
WO2003020260A1 (en) * | 2001-08-31 | 2003-03-13 | Metaproteomics, Llc | Arginine compositions for coordinate modification of multiple cardiovascular risk factors |
CN102557974B (en) * | 2011-05-23 | 2013-12-11 | 常州工程职业技术学院 | Method for preparing L-lysine composite salt |
EP2915434A1 (en) * | 2014-03-04 | 2015-09-09 | Lifewave, Inc. | A nutritional product composition for increasing human growth hormone and nitric oxide production |
KR101627415B1 (en) | 2014-08-13 | 2016-06-03 | 정해윤 | Composition of beauty treatment comprising lysosome for old people |
-
2020
- 2020-01-15 KR KR1020200005364A patent/KR102315140B1/en active IP Right Grant
-
2021
- 2021-01-13 CN CN202180009069.9A patent/CN114980856A/en active Pending
- 2021-01-13 JP JP2022568367A patent/JP2023510655A/en active Pending
- 2021-01-13 US US17/792,844 patent/US20230056593A1/en active Pending
- 2021-01-13 WO PCT/KR2021/000470 patent/WO2021145672A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5019558A (en) * | 1988-05-09 | 1991-05-28 | Georges Cehovic | Method for treating memory disturbances using arginine aspartate |
WO1996028008A2 (en) * | 1996-03-19 | 1996-09-19 | Guerlain S.A. | Novel cosmetic or dermatological compositions for controlling skin ageing |
KR20120118222A (en) * | 2011-04-18 | 2012-10-26 | 상황미인(주) | Cosmetic composition for deoderizing odl men smell by using orental natural materials |
KR20130083103A (en) * | 2012-01-12 | 2013-07-22 | (주)와이즈덤레버러토리 | Anti-aging peptides having depigmentation, anti-wrinkle, anti-oxidation, hair-growth, and angiogenic activities, and uses thereof |
Non-Patent Citations (1)
Title |
---|
NUSSBAUM, M. S. Arginine stimulates wound healing and immune function in elderly human beings. Journal of parenteral and enteral nutrition. 1994, vol. 18, no. 2, p. 194. See page 194, left column. X 1,2,4,5,7,8 A 3,6,9 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210091982A (en) | 2021-07-23 |
JP2023510655A (en) | 2023-03-14 |
CN114980856A (en) | 2022-08-30 |
KR102315140B1 (en) | 2021-10-20 |
US20230056593A1 (en) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011122869A2 (en) | Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care | |
WO2019088720A1 (en) | Cosmetic composition comprising hydrangea serrata extract for anti-skin aging and moisturization | |
WO2014077568A1 (en) | Composition for external use skin preparation, containing thioredoxin | |
WO2010143879A2 (en) | Cosmetic composition for removing wrinkles, containing an abalone extract as an active ingredient | |
WO2013077569A1 (en) | Topical skin treatment composition comprising dendranthema indicum extract | |
WO2021145672A1 (en) | Arginine aspartate-containing composition for suppressing old person smell | |
WO2016010283A1 (en) | Composition containing glycine gracilis oil | |
WO2018111042A2 (en) | Cosmetic composition comprising extract of medicinal herbs as active ingredient | |
WO2020045921A1 (en) | Composition for improving skin transparency and reducing dullness | |
WO2022169246A1 (en) | Cosmetic material composition | |
WO2022177215A1 (en) | Method for promoting antioxidant activity of purple tea leaves | |
WO2018186724A1 (en) | Composition, containing protaetia brevitarsis extract or compound isolated therefrom as active ingredient, for skin moisturization or skin wrinkle relief | |
WO2011126189A1 (en) | Composition for preventing hair loss and stimulating hair growth | |
WO2017074054A1 (en) | Soyasaponin-containing composition for skin whitening | |
KR20180027213A (en) | Composition for skin improvement containing Salvianolic acid C | |
WO2021215709A1 (en) | Whitening cosmetic composition comprising sodium pyruvate as active ingredient | |
WO2021118286A1 (en) | Composition for stimulating and inducing changes in environment around aging skin cells | |
WO2017057891A1 (en) | Composition for prevention of gray hair | |
WO2012115468A2 (en) | Skin whitening composition containing water strained from coagulating bean curd | |
WO2022045638A1 (en) | Composition for improving skin condition containing, as active ingredient, fermented storm petrel nest extract using new strain of genus lactobacillus | |
KR101550727B1 (en) | Composition containing polygalacic acid for improving skin aging and inflammation | |
WO2023158079A1 (en) | Composition comprising fermentation extract of sasa quelpaertensis nakai and fermentation extract of green tea, and various uses thereof | |
WO2009082185A1 (en) | Skin-whitening agent containing platycodin d | |
KR20180061663A (en) | Composition for skin improvement containing dehydroevodiamine | |
WO2015130131A1 (en) | Catechin-free tea water and composition containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21740838 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022568367 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23.12.2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21740838 Country of ref document: EP Kind code of ref document: A1 |